JP2011006491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011006491A5 JP2011006491A5 JP2010232031A JP2010232031A JP2011006491A5 JP 2011006491 A5 JP2011006491 A5 JP 2011006491A5 JP 2010232031 A JP2010232031 A JP 2010232031A JP 2010232031 A JP2010232031 A JP 2010232031A JP 2011006491 A5 JP2011006491 A5 JP 2011006491A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- host
- activated
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 49
- 210000001744 T-lymphocyte Anatomy 0.000 claims 37
- 210000004027 cell Anatomy 0.000 claims 19
- 230000000735 allogeneic effect Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 210000000987 immune system Anatomy 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 239000004005 microsphere Substances 0.000 claims 5
- 102000004127 Cytokines Human genes 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 230000004044 response Effects 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 2
- 102100033467 L-selectin Human genes 0.000 claims 2
- 210000000447 Th1 cell Anatomy 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 230000005745 host immune response Effects 0.000 claims 2
- 230000007236 host immunity Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 210000005087 mononuclear cell Anatomy 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 206010050685 Cytokine storm Diseases 0.000 claims 1
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000919 anti-host Effects 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 206010052015 cytokine release syndrome Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47017103P | 2003-05-13 | 2003-05-13 | |
| US60/470,171 | 2003-05-13 | ||
| US54545004P | 2004-02-18 | 2004-02-18 | |
| US60/545,450 | 2004-02-18 | ||
| US54796604P | 2004-02-26 | 2004-02-26 | |
| US60/547,966 | 2004-02-26 | ||
| US54903204P | 2004-03-01 | 2004-03-01 | |
| US60/549,032 | 2004-03-01 | ||
| US10/838,454 US7435592B2 (en) | 2003-05-13 | 2004-05-04 | Compositions for allogeneic cell therapy |
| US10/838,454 | 2004-05-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532922A Division JP2007500217A (ja) | 2003-05-13 | 2004-05-11 | 同種異系細胞治療：ミラー効果 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011157205A Division JP2011225602A (ja) | 2003-05-13 | 2011-07-15 | 同種異系細胞治療：ミラー効果 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011006491A JP2011006491A (ja) | 2011-01-13 |
| JP2011006491A5 true JP2011006491A5 (https=) | 2011-09-15 |
| JP6030819B2 JP6030819B2 (ja) | 2016-11-24 |
Family
ID=33425748
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532922A Pending JP2007500217A (ja) | 2003-05-13 | 2004-05-11 | 同種異系細胞治療：ミラー効果 |
| JP2010232031A Expired - Lifetime JP6030819B2 (ja) | 2003-05-13 | 2010-10-14 | 同種異系細胞治療：ミラー効果 |
| JP2011157205A Withdrawn JP2011225602A (ja) | 2003-05-13 | 2011-07-15 | 同種異系細胞治療：ミラー効果 |
| JP2014207763A Withdrawn JP2015028072A (ja) | 2003-05-13 | 2014-10-09 | 同種異系細胞治療：ミラー効果 |
| JP2016152801A Pending JP2016190868A (ja) | 2003-05-13 | 2016-08-03 | 同種異系細胞治療：ミラー効果 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006532922A Pending JP2007500217A (ja) | 2003-05-13 | 2004-05-11 | 同種異系細胞治療：ミラー効果 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011157205A Withdrawn JP2011225602A (ja) | 2003-05-13 | 2011-07-15 | 同種異系細胞治療：ミラー効果 |
| JP2014207763A Withdrawn JP2015028072A (ja) | 2003-05-13 | 2014-10-09 | 同種異系細胞治療：ミラー効果 |
| JP2016152801A Pending JP2016190868A (ja) | 2003-05-13 | 2016-08-03 | 同種異系細胞治療：ミラー効果 |
Country Status (6)
| Country | Link |
|---|---|
| US (15) | US7435592B2 (https=) |
| EP (1) | EP1627054A1 (https=) |
| JP (5) | JP2007500217A (https=) |
| CA (1) | CA2525596C (https=) |
| IL (4) | IL171850A (https=) |
| WO (1) | WO2005001074A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| US20110142887A1 (en) * | 2009-12-15 | 2011-06-16 | Immunovative Therapies Ltd. | Methods and compositions for liquidation of tumors |
| US7402431B2 (en) * | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US20070025961A1 (en) | 2003-06-03 | 2007-02-01 | Kenzo Bamba | Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf |
| US7592431B2 (en) * | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| CA2555714C (en) | 2004-02-26 | 2013-12-03 | Immunovative Therapies, Ltd. | Methods for preparing t-cells for cell therapy |
| DK1749090T3 (en) * | 2004-03-01 | 2017-09-04 | Immunovative Therapies Ltd | CELL THERAPY FORMULATION PROCEDURE AND COMPOSITION |
| US8865224B2 (en) * | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
| GB0622400D0 (en) * | 2006-11-10 | 2006-12-20 | Avaris Ab | Novel compositions and uses thereof |
| US9320794B2 (en) | 2006-11-13 | 2016-04-26 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| US7972594B2 (en) | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| US20090232032A1 (en) * | 2007-01-17 | 2009-09-17 | Verbal World, Inc. | Methods and Apparatus for the Manipulation of Conferenced Data |
| US20100325229A1 (en) * | 2008-02-08 | 2010-12-23 | Verbal World, Inc. | Methods and Apparatus for Exchange of Electronic Communications |
| US20120128656A1 (en) * | 2008-05-02 | 2012-05-24 | Immunovative Therapies, Ltd. | Vaccine compositions and methods |
| US9695397B2 (en) | 2008-10-01 | 2017-07-04 | Immunovative Therapies Ltd. | Th1 vaccination priming for active immunotherapy |
| US20120052003A9 (en) * | 2008-05-16 | 2012-03-01 | Szalay Aladar A | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| JP5725489B2 (ja) * | 2008-06-27 | 2015-05-27 | 公立大学法人大阪市立大学 | 医療用組成物および医療用キット |
| US9283184B2 (en) | 2008-11-24 | 2016-03-15 | Massachusetts Institute Of Technology | Methods and compositions for localized agent delivery |
| WO2010099205A1 (en) * | 2009-02-24 | 2010-09-02 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (pml) |
| PH12012502233A1 (en) * | 2010-04-13 | 2022-10-05 | Immunovative Therapies Ltd | Methods and compositions for inhibition of treg cells |
| EP2566954B2 (en) | 2010-05-04 | 2022-11-02 | Yeda Research and Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| WO2012011113A2 (en) | 2010-07-22 | 2012-01-26 | Shai Yarkoni | Regulatory immune cells with enhanced targeted cell death effect |
| JP5006992B2 (ja) * | 2010-08-06 | 2012-08-22 | 株式会社ケーナインラボ | 免疫機能の強化剤 |
| ES2660577T3 (es) * | 2010-08-20 | 2018-03-23 | Immunovative Therapies, Ltd. | Células que expresan características y propiedades citolíticas de Th1 |
| EP2471543A1 (en) * | 2010-12-02 | 2012-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules |
| CA2823782C (en) | 2011-01-10 | 2019-05-07 | Samuel Strober | Enhancement of allogeneic hematopoietic stem cell transplantation |
| CA2832569A1 (en) * | 2011-04-08 | 2012-10-11 | Baylor College Of Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| WO2012151266A1 (en) | 2011-05-03 | 2012-11-08 | Michael Har-Noy | Methods for handling biological drugs containing living cells |
| BR112013028285A2 (pt) * | 2011-05-03 | 2017-01-10 | Immunovative Therapies Ltd | indução de il-12 usando imunoterapia |
| RU2488356C1 (ru) * | 2012-02-28 | 2013-07-27 | Федеральное государственное бюджетное учреждение "Научный центр реконструктивной и восстановительной хирургии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НЦРВХ" СО РАМН) | Способ коррекции иммунных нарушений |
| TWI676481B (zh) * | 2012-05-02 | 2019-11-11 | 以色列商梵提夫免疫療法公司 | 使用免疫療法誘導ｉｌ－１２ |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| CA2782942C (en) * | 2012-07-12 | 2019-08-27 | Canadian Blood Services | Method for inducing immune tolerance using polymer-modified antigenic leukocytes |
| CN102809596B (zh) * | 2012-08-21 | 2014-07-09 | 辉源生物科技（上海）有限公司 | 分离培养新生鼠皮层神经细胞记录t型钙通道电流的方法 |
| US20140065096A1 (en) * | 2012-09-05 | 2014-03-06 | Regen BioPharma, Inc. | Cancer therapy by ex vivo activated autologous immune cells |
| DK3019176T3 (da) | 2013-07-12 | 2020-06-22 | Canadian Blood Services | Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf |
| CA3191031A1 (en) | 2013-09-27 | 2015-04-02 | Massachusetts Institute Of Technology | Carrier-free biologically-active protein nanostructures |
| SG10201908048QA (en) | 2014-01-08 | 2019-10-30 | Immunovative Therapies Ltd | Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
| US10739353B2 (en) | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| WO2017027843A1 (en) | 2015-08-12 | 2017-02-16 | Massachusetts Institute Of Technology | Cell surface coupling of nanoparticles |
| MX2018004875A (es) | 2015-10-22 | 2018-08-01 | Juno Therapeutics Gmbh | Metodos para cultivar celulas y kits y aparatos para ello. |
| CN108883173B (zh) | 2015-12-02 | 2022-09-06 | 阿吉纳斯公司 | 抗体和其使用方法 |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| JP7181517B2 (ja) * | 2018-01-23 | 2022-12-01 | 国立大学法人三重大学 | Ｔ細胞レセプター |
| WO2019221991A1 (en) * | 2018-05-14 | 2019-11-21 | Regents Of The University Of Minnesota | Manipulating arid5b expression in immune cells to promote metabolism, survival, and function |
| EP3834833A4 (en) * | 2018-08-10 | 2022-05-18 | Eutilex Co., Ltd. | CANCER ANTIGEN-SPECIFIC CYTOTOXIC T-CELLS |
| KR102234394B1 (ko) * | 2019-03-08 | 2021-03-31 | 신지섭 | 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 |
| KR102216710B1 (ko) * | 2019-03-27 | 2021-02-17 | 신지섭 | Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물 |
| WO2020210843A2 (en) * | 2019-04-12 | 2020-10-15 | The Johns Hopkins University | Tolerogenic artificial antigen-presenting cells |
| US20210038684A1 (en) | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
| KR20230016178A (ko) | 2020-04-15 | 2023-02-01 | 엘커메스 파마 아일랜드 리미티드 | 혈관신생 억제제와 조합된 면역자극제 |
| US20250319132A1 (en) * | 2024-04-16 | 2025-10-16 | Mirror Biologics, Inc. | Methods and compositions for improving the immune response against viral pathogens |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) * | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| CA2065658A1 (en) * | 1991-04-19 | 1992-10-20 | Tse-Wen Chang | Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators |
| WO1994012196A1 (en) | 1992-11-25 | 1994-06-09 | Tanox Biosystems, Inc. | Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules |
| IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| US6143292A (en) * | 1995-05-25 | 2000-11-07 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| CA2227327A1 (en) * | 1995-07-25 | 1997-02-13 | Celltherapy, Inc. | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
| ES2278390T3 (es) | 1996-05-23 | 2007-08-01 | The Scripps Research Institute | Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+. |
| CA2309206A1 (en) | 1997-11-10 | 1999-05-20 | Arch Development Corporation | Methods for treatment of tumors and tumor cells using ex vivo activated t cells |
| AU1585799A (en) | 1997-11-14 | 1999-06-07 | General Hospital Corporation, The | Treatment of hematologic disorders |
| AU764015C (en) | 1998-07-30 | 2006-03-16 | Regents Of The University Of Minnesota | Ex vivo treatment of allogeneic and xenogeneic T-cells with gp39 antagonists |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US20020127208A1 (en) | 2000-08-31 | 2002-09-12 | Waller Edmund K. | Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
| WO2003038062A2 (en) | 2001-10-31 | 2003-05-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Generation of use of tc1 and tc2 cells |
| JP2004538331A (ja) * | 2001-08-17 | 2004-12-24 | ロジャー ウィリアムス ホスピタル | インサイチュ免疫法 |
| US20030134415A1 (en) | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| CA2555714C (en) | 2004-02-26 | 2013-12-03 | Immunovative Therapies, Ltd. | Methods for preparing t-cells for cell therapy |
| US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
| US8865224B2 (en) * | 2004-10-14 | 2014-10-21 | Immunovative Therapies Ltd. | Allogeneic cellular immunotherapy for opportunistic infection |
| WO2007120128A1 (en) | 2006-04-13 | 2007-10-25 | Immunovative Therapies, Ltd. | Allogeneic cell therapy for treatment of opportunistic infection |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
-
2004
- 2004-05-04 US US10/838,454 patent/US7435592B2/en not_active Expired - Lifetime
- 2004-05-11 WO PCT/US2004/014589 patent/WO2005001074A1/en not_active Ceased
- 2004-05-11 JP JP2006532922A patent/JP2007500217A/ja active Pending
- 2004-05-11 CA CA2525596A patent/CA2525596C/en not_active Expired - Lifetime
- 2004-05-11 EP EP04751794A patent/EP1627054A1/en not_active Withdrawn
-
2005
- 2005-11-09 IL IL171850A patent/IL171850A/en active IP Right Grant
-
2008
- 2008-07-14 US US12/172,594 patent/US7943180B2/en not_active Expired - Lifetime
- 2008-07-15 US US12/173,330 patent/US8076135B2/en not_active Expired - Lifetime
-
2010
- 2010-08-26 US US12/869,490 patent/US8273377B2/en not_active Expired - Fee Related
- 2010-09-21 US US12/887,054 patent/US8778678B2/en active Active
- 2010-09-21 US US12/887,039 patent/US8785188B2/en active Active
- 2010-10-14 JP JP2010232031A patent/JP6030819B2/ja not_active Expired - Lifetime
- 2010-10-21 US US12/909,517 patent/US8354276B2/en not_active Expired - Fee Related
-
2011
- 2011-05-03 US US13/099,871 patent/US8298587B2/en not_active Expired - Fee Related
- 2011-05-03 US US13/099,867 patent/US8728534B2/en not_active Expired - Lifetime
- 2011-07-15 JP JP2011157205A patent/JP2011225602A/ja not_active Withdrawn
-
2012
- 2012-08-28 US US13/596,142 patent/US8679841B2/en not_active Expired - Fee Related
- 2012-11-13 IL IL223010A patent/IL223010A0/en unknown
- 2012-11-13 IL IL223009A patent/IL223009A0/en unknown
- 2012-11-13 IL IL223011A patent/IL223011A/en active IP Right Grant
-
2014
- 2014-02-05 US US14/173,494 patent/US9301977B2/en not_active Expired - Fee Related
- 2014-03-12 US US14/206,785 patent/US9352001B2/en not_active Expired - Fee Related
- 2014-06-11 US US14/301,700 patent/US9511127B2/en not_active Expired - Fee Related
- 2014-10-09 JP JP2014207763A patent/JP2015028072A/ja not_active Withdrawn
-
2016
- 2016-02-11 US US15/041,642 patent/US9782463B2/en not_active Expired - Fee Related
- 2016-08-03 JP JP2016152801A patent/JP2016190868A/ja active Pending
-
2017
- 2017-08-30 US US15/691,395 patent/US10806777B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011006491A5 (https=) | ||
| Fournier et al. | Trial watch: adoptively transferred cells for anticancer immunotherapy | |
| Ames et al. | Advantages and clinical applications of natural killer cells in cancer immunotherapy | |
| ES2769778T3 (es) | Composiciones inmunomoduladoras | |
| JP7105188B2 (ja) | 幹細胞移植方法 | |
| CN114761027A (zh) | 用于免疫细胞扩增的Cbl抑制剂和组合物 | |
| Wang et al. | Adoptive transfer of tumor-primed, in vitro–activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response | |
| AU6682696A (en) | Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease | |
| RU2665359C2 (ru) | Элюирующая матрица и ее применения | |
| Koike et al. | Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma | |
| ES2660577T3 (es) | Células que expresan características y propiedades citolíticas de Th1 | |
| Hübbe et al. | Leveraging endogenous dendritic cells to enhance the therapeutic efficacy of adoptive T-cell therapy and checkpoint blockade | |
| Karachi et al. | Optimizing T cell-based therapy for glioblastoma | |
| JP6802150B2 (ja) | がん治療のための免疫療法 | |
| Bao et al. | Current status of leukemia cytotherapy-exploitation with immune cells | |
| TW202206591A (zh) | 體外增殖自然殺手細胞及自然殺手t細胞之方法 | |
| CN116135969A (zh) | 从外周血中扩增及产生细胞因子诱导的杀伤细胞群的方法 | |
| Ngo et al. | Breast cancer treatment by transplantations of dendritic cells and cytokine-induced killer cells: An update on clinical trials | |
| Boyiadzis et al. | NK cells in cancer immunotherapy: three decades of discovery | |
| Boucault et al. | TRANSIENT ANTIBODY TARGETING OF CD45RC TO PREVENT THE DEVELOPMENT OF ACUTE GRAFT VERSUS HOST DISEASES | |
| Mylonaki et al. | Stem cell viability and proliferation is maintained in vivo using an alginate patch designed for epicardial administration | |
| US20200048608A1 (en) | Method for in vitro activation of immune cells | |
| Ma et al. | IDENTIFICATION AND ISOLATION OF HUMAN HLADR+ CD27+ TREG AS XENO-ANTIGEN TREG SUBSET FOR XENOTRANSPLANTATION | |
| Pezeshki et al. | Immunotherapy with activation of NK cells | |
| Wilson et al. | Stem Cell-Derived Cell Therapy for Cancer |